Study of IMC-P115C in Advanced PRAME-Positive Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 7, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

August 30, 2029

Conditions
PRAME PositiveCancerHLA-A*02:01-positive
Interventions
DRUG

IMC-P115C

IV infusion

Trial Locations (13)

2065

RECRUITING

Melanoma Institute Australia, Wollstonecraft

5000

RECRUITING

Cancer Research South Australia (CRSA), Adelaide

20133

RECRUITING

Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan

20141

RECRUITING

Istituto Europeo di Oncologia, Milan

28034

RECRUITING

Hospital Universitario Ramon y Cajal, Madrid

28040

RECRUITING

START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid

31059

RECRUITING

Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole), Toulouse

69008

RECRUITING

UNICANCER - Centre Leon-Berard (CLB), Lyon

80131

RECRUITING

"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale", Napoli

94805

RECRUITING

Institut Gustave Roussy, Villejuif

06009

RECRUITING

Linear Clinical Research ltd., Nedlands

08035

RECRUITING

Hospital Universitari Vall d Hebron, Barcelona

08908

RECRUITING

Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immunocore Ltd

INDUSTRY

NCT07156136 - Study of IMC-P115C in Advanced PRAME-Positive Cancers | Biotech Hunter | Biotech Hunter